HIV感染与未感染患者结直肠癌中淋巴细胞浸润及PD-1和PD-L1的表达：一项倾向评分匹配队列研究
Lymphocytes Infiltration and Expression of PD-1 and PD-L1 in Colorectal Cancer Between HIV-Infected and Non-HIV-Infected Patients: A Propensity Score Matched Cohort Study.
作者信息
Cao Ye, Wu Qian, Lian Shixian, Deng Li
机构信息
Department of General Surgery, The Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
出版信息
Front Oncol. 2022 Mar 2;12:827596. doi: 10.3389/fonc.2022.827596. eCollection 2022.
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) and expression of programmed cell death 1 (PD-1)/programmed death ligand-1 (PD-L1) are crucial for antitumor immunity. However, the status remains undetermined in HIV-infected colorectal cancer (CRC), limiting the use of immunotherapy in HIV-infected CRC patients.
METHODS
We examined 27 HIV-infected patients and 120 non-HIV-infected patients with CRC from 2015-2020 at Shanghai Public Health Clinical Center. After matching the propensity score, 13 paired patients in the two groups were also compared. The expression of PD-1/PD-L1 as well as tumor-infiltrating CD4, CD8, and CD56 immune cells was examined using multiplex immunofluorescent analysis. The cell density for positive staining was calculated (cells/mm) and compared between HIV-infected and non-HIV-infected groups. In addition, the co-expression of PD-1 on immune cells and PD-L1 on tumor cells was compared in these two groups.
RESULTS
The mean densities of tumor-infiltrating CD4, CD8, CD56 immune cells were 620.2, 261.2, and 0.2 cells/mm, respectively, in HIV-infected colorectal tumors compared with 698.6, 243, and 14 cells/mm in non-HIV-infected tumors. PD-1 expression was 227 cells/mm in HIV-infected tumors and 365.2 cells/mm in non-HIV-infected tumors. Besides, PD-L1 expression was 108.5 cells/mm in HIV-infected tumors and 126.8 cells/mm in non-HIV-infected tumors, and no significant difference was found between the two groups. Similarly, there were no significant differences in the expression of PD-1 on TILs and PD-L1 on tumor cells.
CONCLUSION
HIV-infected CRC patients had similar tumor-infiltrating lymphocytes (CD4 and CD8 T cells) compared to non-HIV-infected controls and substantially similar PD-1 expression on TILs and PD-L1 expression on tumors. These results support the inclusion of HIV-infected CRC patients in future immunotherapy trials.
背景
肿瘤浸润淋巴细胞（TILs）以及程序性细胞死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）的表达对抗肿瘤免疫至关重要。然而，在HIV感染的结直肠癌（CRC）中其状态仍未明确，这限制了免疫疗法在HIV感染的CRC患者中的应用。
方法
我们于2015年至2020年在上海公共卫生临床中心检查了27例HIV感染的CRC患者和120例非HIV感染的CRC患者。在匹配倾向得分后，还比较了两组中的13对配对患者。使用多重免疫荧光分析检测PD-1/PD-L1以及肿瘤浸润的CD4、CD8和CD56免疫细胞的表达。计算阳性染色的细胞密度（细胞/mm）并在HIV感染组和非HIV感染组之间进行比较。此外，比较了这两组中免疫细胞上PD-1与肿瘤细胞上PD-L1的共表达情况。
结果
HIV感染的结直肠肿瘤中肿瘤浸润的CD4、CD8、CD56免疫细胞的平均密度分别为620.2、261.2和0.2细胞/mm，而非HIV感染的肿瘤中分别为698.6、243和14细胞/mm。HIV感染的肿瘤中PD-1表达为227细胞/mm，非HIV感染的肿瘤中为365.2细胞/mm。此外，HIV感染的肿瘤中PD-L1表达为108.5细胞/mm，非HIV感染的肿瘤中为126.
Zotero 插件